Quest Diagnostics Inc

DGX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
Y&?LOCK|x%ns^LOCK|PFR&JZn

Quest Diagnostics: Strong Organic Gains Seen in Quarter, but PAMA Cuts Loom on Horizon

Quest delivered third-quarter results that included revenue and earnings growth of 10% and 26%, respectively. Management indicated it estimates potential PAMA cuts in 2027 could amount to 1% of total revenue.

Sponsor Center